CompletedPhase 2/3

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

United Kingdom16 participantsStarted 1999-11-08

Plain-language summary

To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I

Who can participate

Age range16 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HTLV-I-associated myelopathy Exclusion Criteria: * prior exposure to zidovudine or lamivudine on disease modifying therapy * under age 16

What they're measuring

Timed walk

Timeframe: 6 months

Osame's Motor Disability Score

Timeframe: 6 months

Pain score

Timeframe: 6 months

Urinary frequency

Timeframe: 6 months

HTLV-1 proviral load

Timeframe: 6 months

Trial details

NCT IDNCT00272480

SponsorImperial College London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2002-07-30

View on ClinicalTrials.gov More HTLV-I-associated Myelopathy trials